Thereafter, CASPIAN randomized phase 3 trials also confirmed that the anti-PD-L1 antibody durvalumab in combination with first-line treatment could yield positive results, with an extended median OS of 3 months in patients with ES-SCLC [236]. The gene discussed is CD274; the disease is small cell lung carcinoma.